Nearly one million people in the U.S. are living with Parkinson's disease, a condition for which there is still no known cause or cure. Joseph Mazzulli, PhD, has led two recent studies published in Neuron and Nature Communications uncovering previously unknown cellular mechanisms driving the disease. These studies highlight the potential for new therapeutic targets, including restoring neuronal function for patients with Parkinson's and other neurodegenerative diseases.

New research from the lab of Issam Ben-Sahra, PhD, could rewrite textbooks on our understanding of cellular metabolism and potentially identify new targets for cancer and metabolic diseases such as obesity. The discovery, published in the journal Science, has been praised for its rigorous simplicity and underscores the importance of understanding the molecular mechanisms that underlie specific biological processes.

Jeffrey Gordon, MD, often called "the father of microbiome research," is the 2024 recipient of the Mechthild Esser Nemmers Prize in Medical Science.

In this episode, Gordon discusses the impacts of his long career in gut microbiome research, which has profoundly transformed our understanding of human health. Specifically, he shares the evolution of groundbreaking approaches to treating malnutrition and childhood undernutrition with microbiota-targeted therapies.

The MYC oncogene is notorious in the cancer research world because it is implicated in many advanced or aggressive cancers such as treatment-resistant prostate cancer. In this episode, Sarki Abdulkadir, MD, PhD, shares how his team bucked the conventional notion that the MYC gene is "undruggable" and uncovered a handful of compounds that block MYC gene activity, making prostate cancer tumors sensitive to hormone therapy and opening up a potential new therapeutic target for treatment-resistant prostate cancer.

A team of Northwestern Medicine scientists are conducting a new longitudinal cross-sectional study to investigate why some people see to age faster than others. In this episode, John Wilkins, MD, associate director of the Human Longevity Laboratory at the Potocsnak Longevity Institute, shares details of the study, which will eventually include a variety of interventions aimed at slowing down the aging process.

Northwestern Medicine physician-scientist Jaehyuk Choi, MD, PhD joins the show again to discuss another breakthrough. This time for lupus, a chronic autoimmune condition affecting 300,000 Americans that can cause inflammation in many body parts, including joints, skin, kidneys, blood cells, brain, heart and lungs. Findings by Choi and his lab members not only elucidate the underlying mechanisms of lupus but also suggest potential therapeutic strategies.

For decades, Marcus Peter, PhD, has drilled into an area of research focused on cell death and the roles of toxic and protective short RNAs, with the goal of developing a novel form of cancer treatment. Now, this same line of research has led Peter's team to uncover new insights into the cause of Alzheimer's disease. In this episode, Peter explains his pioneering work in investigating RNA interference in diseases and explains how his lab's latest novel discovery may have relevance to an array of neurodegenerative diseases beyond Alzheimer's.

New advances in digital pathology are revolutionizing the analysis of disease, paving the way for greater accuracy and efficiency when it comes to diagnostics, predicting outcomes and treatment. In this episode, Lee Cooper, PhD, discusses the future of digital and computational pathology and his research on machine learning and pathology, including a recent study published in Nature Medicine on using AI in predicting clinical outcomes for breast cancer patients.

Northwestern University Feinberg School of Medicine is home to a team of premier faculty and staff biostatisticians who are a driving force of data analytic innovation and excellence. In this episode, Denise Scholtens, PhD, a leader in biostatistics at Feinberg, discusses the growing importance of the field of biostatistics and how she leverages her skills to collaborate on several projects in Maternal and Fetal Health.

Northwestern Medicine scientists are at the forefront of research investigating the most effective ways of treating obesity in children and teens and improving their access to care.

In this episode, Justin Ryder, PhD, a clinical and translational obesity scientist at Feinberg, talks about the use of new GLP-1–based medications for childhood obesity and his work on several NIH-funded projects focused on understanding how pediatric obesity impacts chronic disease risk and how biology drives weight regain.